Vaishali Pharma Ltd recommends 1:1 bonus issue and 1:5 stock split
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
The clinical trial will be conducted at 19 sites with 10,335 participants across India
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated